Please login to the form below
Cosentyx
This page shows the latest Cosentyx news and features for those working in and with pharma, biotech and healthcare.
Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
Novartis’ Cosentyx (secukinumab) has been approved by the European Commission (EC) to treat adults with active moderate to severe hidradenitis suppurativa (HS). ... 52. Additionally, approximately 50% of Cosentyx-treated patients had a meaningful
Latest news
-
Novartis’ Cosentyx recommended by CHMP for hidradenitis suppurativa
If approved, Cosentyx will be the first new treatment option for the inflammatory skin disease in nearly a decade. ... 52. Additionally, approximately 50% of Cosentyx-treated patients had a meaningful reduction in HS-related pain at week 52.
-
Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
If approved, Cosentyx will be the first and only interleukin-17 inhibitor for the treatment of moderate-to-severe HS. ... Angelika Jahreis, global head development unit immunology and clinical development excellence at Novartis, said: “This data shows
-
Novartis’ Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis
The risk of flare was reduced by 72% for patients on Cosentyx for two years compared with patients on placebo. ... Safety in this paediatric population was consistent with the known safety profile of Cosentyx for the treatment of adult and paediatric
-
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
The increase was driven by the strong performance of its heart failure combination Entresto (sacubitril/valsartan) which was up by 44%, psoriasis antibody Cosentyx (secukinumab) up by 22%, myelofibrosis drug Jakavi ... Net sales topped $13bn for Q3; top
-
Novartis sees demand returning to pre-COVID-19 levels in Q2 results
growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).
More from news
Approximately 35 fully matching, plus 69 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy
-
Pharma: in search of the sustainable ‘win win’ with the NHS
An Outcomes Guarantee model - Cosentyx promise. Among the many initiatives Novartis is working on with the NHS is ‘The Cosentyx Promise’. ... Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee.
-
Can value-based healthcare take off and reach for the skies?
costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.
-
The good, the bad and the ugly
Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Maker Projects
Our clients include: The NHS NWEH Cancer Research Cosentyx / Novartis Brilinta / AstraZeneca Port of Call We have branches in Manchester and London - to find out more: www.makerprojects.co.
-
90TEN nominated for five Communiqué Awards
Year. 90TEN’s work with Novartis on the global launch of Cosentyx is nominated for Excellence in Media Relations.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
